Anal cancer burden among people with HIV across US states, DC, and major metro areas.

IF 7.7 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute Pub Date : 2026-08-22 DOI:10.1093/jnci/djag285

Ashish A Deshmukh, Haluk Damgacioglu, Kalyani Sonawane, Cameron Haas, Qianlai Luo, Anna Satcher Johnson, Eric A Engels, Meredith S Shiels

{"title":"Anal cancer burden among people with HIV across US states, DC, and major metro areas.","authors":"Ashish A Deshmukh, Haluk Damgacioglu, Kalyani Sonawane, Cameron Haas, Qianlai Luo, Anna Satcher Johnson, Eric A Engels, Meredith S Shiels","doi":"10.1093/jnci/djag285","DOIUrl":null,"url":null,"abstract":"Background: Anal cancer screening is recommended for people with HIV in the United States (US). Because HIV prevalence varies geographically, the distribution of anal cancer diagnoses occurring among people with HIV may also differ by geography. Characterizing geographic variation can help identify areas needing enhanced screening infrastructure and outreach.Methods: Using data from the HIV/AIDS Cancer Match Study, US cancer registries, and CDC's National HIV Surveillance System, we estimated the proportion of incident anal squamous cell carcinomas (SCC) among people with HIV across the 50 states, the District of Columbia (DC), and major metropolitan statistical areas (MSAs).Results: During 2010-2019, an average of 2,160 anal SCC diagnoses occurred annually among males, 414 (20.1%; Uncertainty Interval [UI]=19.4%-20.6%) among males with HIV. Among females, 58 of an average 4,099 annual anal SCC diagnoses (1.4%; UI = 1.3%-1.5%) occurred among females with HIV. Geographic variation among males was substantial. California had the highest annual number of anal SCC diagnoses among males with HIV (70/239; 29.2% [UI = 26.7%-31.8%]), followed by New York (48/161; 29.8% [UI = 26.3%-33.4%]), Florida (42/182; 23.1% [UI = 20.3%-26.1%]), Texas (36/132; 27.0% [UI = 23.7%-30.4%]), and Georgia (20/80; 25.2% [UI = 20.9%-29.8%]). New York had the highest annual number of diagnoses among females with HIV (10/263; 3.7% [UI = 3.0%-4.5%]). Across MSAs, the highest burden was in New York-Jersey City-White Plains (57 diagnoses [UI = 43-73]), with several MSAs in California, Texas, and Florida also showing a high burden.Discussion: Geographic differences underscore the need for targeted anal cancer screening outreach and implementation.","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNCI Journal of the National Cancer Institute","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jnci/djag285","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Anal cancer screening is recommended for people with HIV in the United States (US). Because HIV prevalence varies geographically, the distribution of anal cancer diagnoses occurring among people with HIV may also differ by geography. Characterizing geographic variation can help identify areas needing enhanced screening infrastructure and outreach.

Methods: Using data from the HIV/AIDS Cancer Match Study, US cancer registries, and CDC's National HIV Surveillance System, we estimated the proportion of incident anal squamous cell carcinomas (SCC) among people with HIV across the 50 states, the District of Columbia (DC), and major metropolitan statistical areas (MSAs).

Results: During 2010-2019, an average of 2,160 anal SCC diagnoses occurred annually among males, 414 (20.1%; Uncertainty Interval [UI]=19.4%-20.6%) among males with HIV. Among females, 58 of an average 4,099 annual anal SCC diagnoses (1.4%; UI = 1.3%-1.5%) occurred among females with HIV. Geographic variation among males was substantial. California had the highest annual number of anal SCC diagnoses among males with HIV (70/239; 29.2% [UI = 26.7%-31.8%]), followed by New York (48/161; 29.8% [UI = 26.3%-33.4%]), Florida (42/182; 23.1% [UI = 20.3%-26.1%]), Texas (36/132; 27.0% [UI = 23.7%-30.4%]), and Georgia (20/80; 25.2% [UI = 20.9%-29.8%]). New York had the highest annual number of diagnoses among females with HIV (10/263; 3.7% [UI = 3.0%-4.5%]). Across MSAs, the highest burden was in New York-Jersey City-White Plains (57 diagnoses [UI = 43-73]), with several MSAs in California, Texas, and Florida also showing a high burden.

Discussion: Geographic differences underscore the need for targeted anal cancer screening outreach and implementation.

查看原文本刊更多论文

美国各州、哥伦比亚特区和主要都市地区艾滋病毒感染者的肛门癌负担。

背景：在美国，建议艾滋病毒感染者进行肛门癌筛查。由于艾滋病毒的流行在地理上存在差异，因此艾滋病毒感染者中肛门癌的诊断分布也可能因地理而异。描述地理差异有助于确定需要加强筛查基础设施和推广的地区。方法：使用来自HIV/AIDS癌症匹配研究、美国癌症登记处和CDC国家HIV监测系统的数据，我们估计了50个州、哥伦比亚特区（DC）和主要大都市统计区（msa）的HIV感染者中肛门鳞状细胞癌（SCC）的发生率。结果：2010-2019年期间，男性平均每年发生2160例肛门SCC诊断，其中414例（20.1%；不确定区间[UI]=19.4%-20.6%）为艾滋病毒感染者。在女性中，每年平均4,099例肛门SCC诊断中有58例（1.4%;UI = 1.3%-1.5%）发生在携带HIV的女性中。男性之间的地理差异很大。在男性HIV感染者中，加利福尼亚州每年肛门SCC诊断数量最多（70/239;29.2% [UI = 26.7%-31.8%]），其次是纽约州（48/161;29.8% [UI = 26.3%-33.4%]）、佛罗里达州（42/182;23.1% [UI = 20.3%-26.1%]）、德克萨斯州（36/132;27.0% [UI = 23.7%-30.4%]）和佐治亚州（20/80;25.2% [UI = 20.9%-29.8%]）。纽约女性HIV确诊人数最高（10/263;3.7% [UI = 3.0%-4.5%]）。在所有msa中，负担最高的是纽约-泽西市-白原市（57例诊断[UI = 43-73]），加利福尼亚州、德克萨斯州和佛罗里达州的几个msa也显示出高负担。讨论：地理差异强调了有针对性的肛门癌筛查推广和实施的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JNCI Journal of the National Cancer Institute 医学-肿瘤学

CiteScore

17.00

自引率

2.90%

发文量

203

审稿时长

4-8 weeks

期刊介绍： The Journal of the National Cancer Institute is a reputable publication that undergoes a peer-review process. It is available in both print (ISSN: 0027-8874) and online (ISSN: 1460-2105) formats, with 12 issues released annually. The journal's primary aim is to disseminate innovative and important discoveries in the field of cancer research, with specific emphasis on clinical, epidemiologic, behavioral, and health outcomes studies. Authors are encouraged to submit reviews, minireviews, and commentaries. The journal ensures that submitted manuscripts undergo a rigorous and expedited review to publish scientifically and medically significant findings in a timely manner.